XML 14 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2017
Jun. 30, 2017
Current assets:    
Cash and cash equivalents $ 87.9 $ 102.4
Marketable investment securities 60.4 48.3
Prepaid expenses 9.5 12.7
Inventory 38.9 42.2
Trade accounts receivable, less allowance for doubtful accounts of $8.6 September 30, 2017 and $8.2 June 30, 2017 113.2 105.6
Prepaid taxes 8.8 0.2
Other receivables 6.9 5.7
Total current assets 325.6 317.1
Property, plant and equipment, net 49.8 51.1
Long-term marketable investment securities 50.1 48.5
Intangibles, net 483.8 491.6
Goodwill 319.0 316.1
Total assets 1,228.3 1,224.4
Current liabilities:    
Accounts payable 22.5 22.0
Accrued liabilities 59.8 65.6
Short-term contingent consideration 54.0 127.3
Deferred revenue 2.9 2.6
Total current liabilities 139.2 217.5
Unrecognized tax benefits 31.9 25.2
Other long-term liabilities 7.4 7.2
Contingent consideration 13.8 13.2
Long-term debt 74.2 99.1
Long-term deferred taxes 91.2 84.4
Total liabilities 357.7 446.6
Commitments and contingencies
Stockholders’ equity:    
Common stock, 69.2 and 68.4 shares outstanding at September 30, 2017 and June 30, 2017 respectively 0.7 0.7
Additional paid-in capital 859.6 851.4
Accumulated other comprehensive loss (2.2) (5.5)
Retained earnings (deficit) 12.8 (68.4)
Total Myriad Genetics, Inc. stockholders’ equity 870.9 778.2
Non-Controlling Interest (0.3) (0.4)
Total stockholders' equity 870.6 777.8
Total liabilities and stockholders’ equity $ 1,228.3 $ 1,224.4